A novel αiIbβ3 antagonist for prehospital therapy of myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 10, 2014, Pages 2321-2329

  Li, Jihong ^a   Vootukuri, Spandana ^a   Shang, Yi ^b   Negri, Ana ^b   Jiang, Jian Kang ^c   Nedelman, Mark ^d   Diacovo, Thomas G ^e   Filizola, Marta ^b   Thomas, Craig J ^c   Coller, Barry S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Ekam Imaging   (United States)

^e New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Blood platelets; Myocardial infarction

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; RUC 2; RUC 4; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR; ANTITHROMBOCYTIC AGENT; CHLORIDE; FERRIC CHLORIDE; FERRIC ION; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; PROTEIN BINDING; PYRIMIDINONE DERIVATIVE; RUC-4 COMPOUND; THIADIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; AUTOINJECTOR; BINDING SITE; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; EMERGENCY CARE; FERRIC CHLORIDE-INDUCED THROMBOSIS; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; MACACA FASCICULARIS; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CAROTID STENOSIS; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; EMERGENCY HEALTH SERVICE; GENETICS; MALE; METABOLISM; MYOCARDIAL INFARCTION; PROTEIN CONFORMATION; SOLUBILITY; THROMBOCYTE; THROMBOSIS; TRANSGENIC MOUSE;

ANIMALS; BINDING SITES; BLOOD PLATELETS; CAROTID STENOSIS; CHLORIDES; DISEASE MODELS, ANIMAL; EMERGENCY MEDICAL SERVICES; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR DYNAMICS SIMULATION; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; PROTEIN CONFORMATION; PYRIMIDINONES; SOLUBILITY; THIADIAZOLES; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84913554789     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303724     Document Type: Article

References (48)

1. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112:3011-3025.
2. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev. 2010;8:CD002130.
3. Bledzka K, Smyth SS, Plow EF. Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res. 2013;112:1189-1200.
4. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59-67.
5. Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentin TE, Chong BH; Scientific and Standardization Committee of The International Society On Thrombosis and Haemostasis. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost. 2006;4:678-679.
6. Hassan AK, Jukema JW, van der Laarse A, Hasan-Ali H, Wolterbeek R, van der Kley F, Spano F, Atsma DE, Schalij MJ. Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment. EuroIntervention. 2009;4:662-668.
7. Hassan AK, Liem SS, van der Kley F, Bergheanu SC, Wolterbeek R, Bosch J, Bootsma M, Zeppenfeld K, van der Laarse A, Atsma DE, Jukema JW, Schalij MJ. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv. 2009;74:335-343.
8. De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart. 2008;94:1548-1558.
9. Rakowski T, Siudak Z, Dziewierz A, Birkemeyer R, Legutko J, Mielecki W, Depukat R, Janzon M, Stefaniak J, Zmudka K, Dubiel JS, Partyka L, Dudek D. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry. Am Heart J. 2009;158:569-575.
10. Xu Q, Yin J, Si LY. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI. Int J Cardiol. 2013;162:210-219.
11. De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, DE Carlo M, Rakowski T, Gyongyosi M, Dudek D. Early glycoprotein IIb-IIIa inhibitors in primary angioplastyabciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost. 2011;9:2361-2370.
12. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Baldazzi F, Dall'Ara G, Nardini P, Gianstefani S, Guastaroba P, Grilli R, Branzi A. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J. 2009;30:33-43.
13. Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A, Neuman FJ, Effron MB, Barnathan ES, Topol EJ, Ellis SG; FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. J Am Coll Cardiol Cardiovasc Interv. 2009;2:917-924.
14. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des. 2004;10:1587-1596.
15. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: why don't they work? Am J Cardiovasc Drugs. 2001;1:421-428.
16. Jennings LK, White MM. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J. 1998;135(5 pt 2 su):S179-S183.
17. Honda S, Tomiyama Y, Aoki T, Shiraga M, Kurata Y, Seki J, Matsuzawa Y. Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling. Blood. 1998;92:3675-3683.
18. Dickfeld T, Ruf A, Pogatsa-Murray G, Müller I, Engelmann B, Taubitz W, Fischer J, Meier O, Gawaz M. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thromb Res. 2001;101:53-64.
19. Blue R, Murcia M, Karan C, Jirousková M, Coller BS. Application of high-throughput screening to identify a novel alphaIIb-specific smallmolecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. Blood. 2008;111:1248-1256.
20. Hantgan RR, Stahle MC. Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition. Biochemistry. 2009;48:8355-8365.
21. Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, Eisenhardt SU, Ahrens I, Bode C, Jackson SP, Peter K. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol. 2007;27:e9-15.
22. Du XP, Plow EF, Frelinger AL 3rd, O'Toole TE, Loftus JC, Ginsberg MH. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell. 1991;65:409-416.
23. Frelinger AL 3rd, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001;104:1374-1379.
24. Hantgan RR, Stahle MC, Connor JH, Connor RF, Mousa SA. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost. 2007;5:542-550.
25. Kouns WC, Kirchhofer D, Hadváry P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80:2539-2547.
26. Ndrepepa G, Guerra E, Schulz S, Fusaro M, Cassese S, Kastrati A. Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. J Thromb Thrombolysis. 2014.
27. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor inhibitors-part II. Clin Cardiol. 2003;26:401-406.
28. Osmancik P, Jirmar R, Hulikova K, Peroutka Z, Pompachova A, Motovska Z, Widimsky P. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv. 2010;75:158-166.
29. Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schömig E, Verheugt FW, ten Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122:776-781.
30. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797-804.
31. Asmussen S, Maybauer DM, Maybauer MO. Intramuscular versus intravenous benzodiazepines for status epilepticus. N Engl J Med. 2012;366: 1943-1944.
32. 2+ binding to the MIDAS. Sci Transl Med. 2012;4:125ra32.
33. Zhu J, Zhu J, Negri A, Provasi D, Filizola M, Coller BS, Springer TA. Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening. Blood. 2010;116:5050-5059.
34. Jiang JK, McCoy JG, Shen M, et al. A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor. Bioorg Med Chem Lett. 2014;24:1148-1153.
35. Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488-1494.
36. Kereiakes DJ, Lorenz T, Young JJ, Kukielka G, Mueller MN, Nanniazzi-Alaimo L, Phillips DR. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis. 2001;12:123-127.
37. Blue R, Kowalska MA, Hirsch J, Murcia M, Janczak CA, Harrington A, Jirouskova M, Li J, Fuentes R, Thornton MA, Filizola M, Poncz M, Coller BS. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood. 2009;114:195-201.
38. Magallon J, Chen J, Rabbani L, Dangas G, Yang J, Bussel J, Diacovo T. Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents. Circulation. 2011;123:319-326.
39. Verheugt FW, Gersh BJ, Armstrong PW. Aborted myocardial infarction: a new target for reperfusion therapy. Eur Heart J. 2006;27:901-904.
40. Bates ER, Jacobs AK. Time to treatment in patients with STEMI. N Engl J Med. 2013;369:889-892.
41. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307:1925-1933.
42. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, Ohman EM, Peterson ED; CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006;114:1380-1387.
43. De Carlo M, Borelli G, Gistri R, Ciabatti N, Mazzoni A, Arena M, Petronio AS. Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes. Catheter Cardiovasc Interv. 2009;74:408-415.
44. Qureshi AI, Hussain MS, Nasar A, Kirmani JF, Divani AA, Ahmed S, Suri MF. Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States. Cardiovasc Drugs Ther. 2005;19:371-373.
45. Rakowski T, Zalewski J, Legutko J, Bartus S, Rzeszutko L, Dziewierz A, Sorysz D, Bryniarski L, Zmudka K, Kaluza GL, Dubiel JS, Dudek D. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J. 2007;153:360-365.
46. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010. Circulation. 2013;128:2577-2584.
47. Goel K, Pinto DS, Gibson CM. Association of time to reperfusion with left ventricular function and heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: a systematic review. Am Heart J. 2013;165:451-467.
48. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation. 1997;95:1755-1759.